ProPhase Labs, Inc. (PRPH)
OTC Markets
Key stats Fiscal year 2025
Income statement
- Revenue
- 4,345,000 -35.8%
- Net income
- -14,743,000
- Gross profit
- 1,384,000
- Operating income
- -18,047,000
- Earnings per share
- -1.74
- R&D expense
- 107,000
Growth and profitability
- Gross margin
- 31.85
- Operating margin
- -415.35
- Net margin
- -339.31
- Return on equity
- -420.27
- Return on assets
- -24.62
- Free cash flow margin
- -192.04
Balance sheet
- Total assets
- 59,871,000
- Total liabilities
- 56,363,000
- Shareholders' equity
- 3,508,000
- Cash and equivalents
- 90,000
- Current ratio
- 0.06
Cash flow and ratios
- Operating cash flow
- -8,344,000
- Free cash flow
- -8,344,000
Shareholder returns
- Shares outstanding
- 15,592,556
- Book value per share
- 0.22
Company information
- Headquarters
- New York, NY
- Exchange
- OTC Markets
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
ProPhase Labs, Inc. trades on OTC Markets under the ticker symbol PRPH. This page brings together its price chart, company profile, key financial figures and technical indicators.